Fig. 2

PSMC5 expression in microglia upon after luteolin treatment. A, B Protein spots identified using 2-DE gels between LPS and luteolin (Lut) treatment groups in BV2 cells, and differences in spot intensity shown by MALDI–TOF-MS to identify PSMC5. C Lut treatment downregulated PSMC5 protein levels in BV2 cells. *p < 0.05 and **p < 0.01 versus the LPS group. D PSMC5 protein levels in mouse brain at different time points in mice treated with LPS. *p < 0.05 and **p < 0.01 versus the control group. E PSMC5 protein levels in the mouse brain after i.c.v. shRNA PSMC5 injection at different times and volumes. F PSMC5 protein levels in the mouse brain after i.c.v. shRNA PSMC5 injection. n = 3–4, data are expressed as means ± SEM, *p < 0.05 and **p < 0.01 versus the control, saline, shRNA PSMC5, and NC groups; ^#P < 0.05, ^##P < 0.01 versus the shRNA PSMC5 + LPS group